Theranexus (XPAR:ALTHX) LT-Debt-to-Total-Asset : 0.50 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Theranexus LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Theranexus's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.50.

Theranexus's long-term debt to total assets ratio increased from Dec. 2022 (0.41) to Dec. 2023 (0.50). It may suggest that Theranexus is progressively becoming more dependent on debt to grow their business.

Theranexus LT-Debt-to-Total-Asset Historical Data

The historical data trend for Theranexus's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theranexus LT-Debt-to-Total-Asset Chart

Theranexus Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.18

0.33

0.32

0.41

0.50

Theranexus Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial												0.32	0.26	0.41	0.49	0.50

Theranexus LT-Debt-to-Total-Asset Calculation

Theranexus's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	3.643	/	7.238
	=

Theranexus's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	3.643	/	7.238
	=

Theranexus (XPAR:ALTHX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Theranexus LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Theranexus's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Theranexus (XPAR:ALTHX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theranexus SA (XPAR:ALTHX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

3VG:Germany

Address

60 avenue Rockefeller, Pepiniere Laennec, Lyon, FRA, 69008

Website

https://www.theranexus.com

Theranexus SA is a France based biopharmaceutical company. It is engaged in developing drug candidates to be used in the treatment of central nervous system (CNS) disorders. The company's therapeutics platform is based on simultaneously targeting neurons and glial cells by creating and developing innovative combinations of two distinct drugs: a CNS drug targeting neuronal activity; and a drug targeting glial cells. The drug candidates of the organization are THN102 to treat excessive daytime sleepiness in Parkinson's disease, THN201 for the treatment of neurocognitive disorders in Alzheimer's disease and THN101 for neuropathic pain.

Theranexus (XPAR:ALTHX) Headlines

No Headlines